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Degenerative mitral valve disease often leads to leaﬂet prolapse due to chordal elongation or rupture, and resulting in mitral valve regur-
gitation. Guideline referral for surgical intervention centres primarily on symptoms and ventricular dysfunction. The recommended treatment
for degenerative mitral valve disease is mitral valve reconstruction, as opposed to valve replacement with a bioprosthetic or mechanical valve,
because valve repair is associated with improved event free survival. Recent studies have documented a signiﬁcant number of patients are not
referred in a timely fashion according to established guidelines, and when they are subjected to surgery, an alarming number of patients
continue to undergo mitral valve replacement. The debate around appropriate timing of intervention for asymptomatic severe mitral
valve regurgitation has put additional emphasis on targeted surgeon referral and the need to ensure a very high rate of mitral valve
repair, particularly in the non-elderly population. Current clinical practice remains suboptimal for many patients, and this review explores
the need for a ‘best practice revolution’ in the ﬁeld of degenerative mitral valve regurgitation.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Degenerative mitral valve disease is a common disorder affecting
around 2% of the population.
1 The most common ﬁnding in
patients with degenerative valve disease is leaﬂet prolapse due to
elongation or rupture of the chordal apparatus, resulting in
varying degrees of mitral valve regurgitation due to leaﬂet malcoap-
tation during ventricular contraction. The emphasis of clinical
decision-making in patients with degenerative disease centres
around the severity of regurgitation and its impact on symptom
status, ventricular function and dimension, the sequelae of systolic
ﬂow reversal such as atrial dilatation/ﬁbrillation and secondary
pulmonary hypertension, and the risk of sudden death.
1–4
Controversy exists as to whether early surgical intervention in
asymptomatic patients, before the onset of ventricular changes,
improves the outcome of patients with chronic severe degenerative
mitral valve disease.
4–7 This debate has put emphasis on the lack of
predictability of mitral valve repair, despite broad consensus that
this is the procedure of choice for patients undergoing surgical inter-
vention.Theconﬁdencegapinpredictingsuccessfulmitralvalverepair
isoneofthefactorsresponsibleforthelackofadherencetoguidelines
directedtowardtimelyreferralofpatientswithindicationsforsurgery.
Anemergingaccordisbuildingthatcurrentmedicalandsurgicalprac-
tice often results in suboptimal care for the individual patient with
degenerativemitralvalvedisease,andindeedaparadigmshiftor‘revo-
lution’ through education is not only predictable but essential to
advance the ﬁeld. All practicing cardiovascular specialists should
have familiarity with the ‘state of art’ in terms of degenerative
disease differentiation, timing of intervention, and surgical techniques
and results in order to improve patient care.
8
The spectrum of degenerative
mitral valve disease
Mitral valve prolapse due to degenerative disease is deﬁned by a
spectrum of lesions, varying from simple chordal rupture involving
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scallop of the posterior leaﬂet) in an otherwise normally shaped
valve, to multi-segment prolapse involving one or both leaﬂets in
a valve with signiﬁcant excess tissue and large annular size; thus,
a spectrum of degenerative disease is evident in clinical practice,
which has important clinical and surgical implications (Figure 1).
8–11
Fibroelastic deﬁciency
FibroelasticdeﬁciencyisaconditioncharacterizedbyCarpentierand
co-workers, who realized that not all degenerative valve disease
involved giant excess tissue as originally proposed by Barlow in the
1960’s.
12–13 Carpentier described a condition associated with a
ﬁbrillin deﬁciency which often leads to a rupture of one or more
thinned and elongated chordae, usually involving the middle
scallop of the posterior leaﬂet. In selected cases valve segments
may appear completely normal with the isolated ﬁnding of thinned
chordae (Figure 1). In other patients, the prolapsing segment devel-
ops myxomatous changes with mucopolysaccharide accumulation
in the valve mucosa, causing a proliferative condition of the affected
leaﬂetsegment(Figure1).Thekeytomakingthedistinctionofﬁbroe-
lastic deﬁciency rests in the condition of adjacent leaﬂet segments,
which are usually normal or even thinned out with a translucent
quality, and are of normal size and height (Figure 2A).
9–11 The valve
annular size as deﬁned by anterior leaﬂet surface area (measured
with commercially available ring sizers) is generally normal (28–
32 mm).
11 Patients are typically over the age of 60 years at the
time of surgical referral, and have a relatively short clinical history.
Echocardiographic ﬁndings include an isolated segmental prolapse
due to chordal rupture leading to holosystolic mitral regurgitation,
evident on echocardiographic imaging (Figure 2B and C).
14–15
Barlow’s disease
In contrast to ﬁbroelastic deﬁciency, Barlow’s disease is character-
ized by diffuse excess tissue (Figure 1).
9–11,16–17 Valve size is
generally quite large, and multiple segments are usually affected
with myxomatous pathological changes, resulting in ‘ﬂoppy leaﬂets’
that are thickened and distended. Diffuse chordal elongation in
additiontochordalruptureistheruleasopposedtoasimpleisolated
chordal rupture. Typically the valve size based on anterior leaﬂet
surface area corresponds to a mitral ring size of ≥36 mm. Severe
annular dilatation with varying degrees of annular calciﬁcation may
beobserved,andsubvalvularﬁbrosisandcalciﬁcationofthepapillary
muscles(usuallytheanteriorpapillarymuscle)mayoccur.
17Patients
withBarlow’sdiseasearegenerallyyounger(,60yearsofage)atthe
time of surgical referral, and typically have a long history of a regur-
gitant murmur.
9–10 Forme fruste was the descriptive label Carpen-
tier gave to certain mitral valves with some but not all pathologic
features of Barlow’s disease, recognizing there was a spectrum of
lesions.
10–11 Echocardiographic ﬁndings include mid-systolic and
often complex regurgitation with multiple jets consistent with
diffuse myxomatous disease (Figure 2C and D).
14–15 Billowing of
one or both leaﬂets is often seen. The posterior leaﬂet is often dis-
placed toward the leftatrial(LA) freewall awayfrom the ventricular
hinge, resulting in a cul-de-sac along the posterior portion of the
annulus, which may be a precipitating factor for annular ﬁssures
and calciﬁcation.
17–18
Echocardiographic assessment
of mitral regurgitation
Echocardiography is the diagnostic method of choice to assess
patients with mitral valve disease. The identiﬁcation of the aetiol-
ogy and underlying lesions that result in mitral valve dysfunction
is of particular importance for management decisions; patients
with degenerative mitral regurgitation should be differentiated
from those with other forms of mitral disease such as rheumatic
or functional mitral regurgitation. A precise morphologic assess-
ment is necessary to predict the rates of successful reconstructive
valve surgery. In most cases, the aetiology and localization of the
pathology (assessment of the involved leaﬂets and segments) can
Figure 1 Spectrum of degenerative mitral disease. There is a spectrum of degenerative disease ranging from ﬁbroelastic deﬁciency (FED) to
Barlow’s disease. In isolated FED there is a deﬁciency of collagen, with thin transparent leaﬂets and typically a ruptured thin chord. In long-
standing prolapse, secondary myxomatous pathologic changes may occur in the prolapsing segment, resulting in leaﬂet thickening and expansion
(FED+). Forme fruste designates degenerative disease with excess tissue with myxomatous changes in usually more than one leaﬂet segment,
but usually does not involve a large valve size, distinguishing it from Barlow’s disease. In the later, the hallmarks are large valve size, with diffuse
myxomatous changes and excess leaﬂet tissue, with thickened, elongated, and often ruptured chordae.
Degenerative mitral valve regurgitation 1959be identiﬁed by transthoracic echocardiography.
19 A systematic
approach is recommended, since a combination of lesions may
be contributing to the valve dysfunction and a satisfactory correc-
tion requires addressing all of them at the time of surgery. Trans-
oesophageal echocardiography allows a more precise assessment
and should be performed when the information obtained by trans-
thoracic echocardiography is insufﬁcient. Intraoperative transoeso-
phageal echocardiography is nowadays systematically performed in
mitral repair surgery and provides important information, and
allows for an immediate assessment of the operative result. The
availability of 3D echocardiography provides additional information
to determine the exact localization of lesions.
15,20
The echocardiographic quantiﬁcation of mitral regurgitation
severity is sometimes challenging and should comprise an integra-
tive approach of qualitative and quantitative signs.
21 Because of its
clinical implication, the identiﬁcation of severe mitral regurgitation
is of particular importance. Several parameters that can be cate-
gorized into structural, Doppler echocardiographic and quantitat-
ive parameters should be assessed and considered together for
the quantiﬁcation of mitral regurgitation severity.
21 In addition to
quantitative parameters, speciﬁc and supportive signs of severity
have been deﬁned. Speciﬁc signs for the presence of a severe
mitral regurgitation include a vena contracta width ≥0.7 cm with
a large central regurgitant jet (area .40% of left atrium) or with
a wall-impinging jet of any size, a large ﬂow convergence, systolic
ﬂow reversal in the pulmonary veins and a prominent ﬂail mitral
valve leaﬂet or ruptured chordal apparatus. Supportive signs
include a dense, triangular CW Doppler MR jet, an E-wave domi-
nant mitral inﬂow (E . 1.2 m/s) as well as an enlarged left ventri-
cular (LV) and LA (particularly with normal LV function). Among
the quantitative parameters, an effective regurgitant oriﬁce area
≥40 cm
2, a regurgitant volume ≥60 mL, and a regurgitant fraction
≥50% characterize severe mitral regurgitation. Since most of the
above measurements have limitations, the information of several
factors should be combined. In addition, echocardiography allows
assessments of pulmonary arterial pressure and LV size and func-
tion, which are all important in the timing of mitral valve surgery.
The assessment of the severity of mitral regurgitation should be
correlated with clinical evaluation.
Timing of surgery
Surgical intervention for chronic severe mitral valve regurgitation is
usually triggered by the occurrence of symptoms, declining LV
function, signiﬁcant LV enlargement, or the development of atrial
ﬁbrillation or severe pulmonary hypertension.
22–23 Over the
past few years the concept of earlier surgical intervention has
been proposed, although controversy exists whether asympto-
matic patients with severe mitral regurgitation and normal LV func-
tion should undergo elective mitral valve repair.
4–5,7,24–26
Although the debate regarding asymptomatic patients is ongoing,
emerging data suggest a wide clinical practice gap in appropriate
referral of patients with guideline-deﬁned indications for surgical
intervention; both issues are clariﬁed below.
The debate around patients with
asymptomatic severe mitral
regurgitation
Enriquez-Sarano et al.
4 noted high event rates, including sudden
death, in 198 asymptomatic patients with quantitatively graded
Figure 2 Echocardiographic differentiation of degenerative mitral disease. (A) Fibroelastic deﬁciency with a ruptured thin chord to P3 (posterior
lateral scallop). (B) Three-dimensional transoesophageal echocardiography volume rendering of the same valve. (C) Three-dimensional rendering
of the same valve from a three-dimensional data set using quantitative analysis (red area corresponds to prolapsing area). (D) Barlow’s disease with
multi-segment prolapse and excess leaﬂet tissue. (E) Three-dimensional rendering volume rendering of the same valve. (F) Three-dimensional
rendering of the same valve from a three-dimensional data set using quantitative analysis (red areas correspond to prolapsing areas).
D.H. Adams et al. 1960severe degenerative mitral regurgitation (effective regurgitant
oriﬁce area ≥40 mm
2), leading them to recommend prompt
surgery in such patients. However, in this study patients were
not prospectively followed and included some patients with an
ejection fraction between 50 and 60%, which would be operated
according to recent guidelines. In contrast, Rosenhek et al. pub-
lished a contemporaneous series involving 132 asymptomatic
patients with semi-quantitatively graded severe degenerative
mitral regurgitation and noted a good outcome with a watchful
waiting strategy. During an 8-year interval, 45% of patients had
an event (but not sudden death), with events occurring at a
regular pace. Two-thirds of the patients fulﬁlling indications for
surgery became symptomatic, whereas one-third of the patients
required surgery because of asymptomatic LV dysfunction or
enlargement, or new onset atrial ﬁbrillation or pulmonary hyper-
tension.
7 Kang et al.
5 published the results of their prospective reg-
istry involving 161 asymptomatic patients with semi-quantitatively
graded severe degenerative mitral regurgitation who were sub-
jected to early surgery, compared with 268 similar patients
managed by watchful waiting over a 9 year period of follow-up.
They found a 99% cardiac event-free survival in operated patients,
compared with 85% in patients under a strategy of continued
medical observation. The cardiac deaths occurring in the group
of patients that was initially managed conservatively, however,
may have not have been related to conservative strategy; urgent
surgery was proposed but refused by ﬁve of the six patients
who died of congestive heart failure and one sudden death
occurred in a patient who had become symptomatic. Nonetheless
three cases of sudden death occurred in asymptomatic patients.
Montant et al.
6 recently examined outcomes in patients with
severe degenerative mitral regurgitation by semi-quantitative echo-
cardiographic assessment, reporting on 67 patients managed with a
conservative approach and 125 patients subjected to early mitral
valve repair. Ten year survival was signiﬁcantly lower in conserva-
tively managed patients compared with those operated early
(50+7% vs. 86+4%, P , 0.0001). Interestingly, these authors
also documented better survival and higher referral to surgery in
conservatively managed patients seeing cardiologists regularly
compared with those with irregular follow-up, but their survival
still did not match those subjected to early surgery.
Unfortunately, no attempt was made in any of these studies to
differentiate the aetiology of degenerative mitral valve disease,
although patients were older in Enriquez-Sarano’s study (mean age
63+14 years) and Montant’s study (mean age 63+13 years) vs.
Rosenhek’s study (mean age 55+15 years) and Kang’s study
(mean age 50+15 years), suggesting that more patients in the
Mayo and Brussels series may have had ﬁbroelastic deﬁciency. The
results of Rosenhek et al. emphasized the need for careful patient
and echocardiographic assessment in a dedicated valve clinic with
strict adherence to guideline referral if a strategy of watchful
waiting is undertaken, a point reinforced by Montant’s data.
Several additional prognostic factors allowing to risk stratify
asymptomatic patients with mitral valve regurgitation have been
proposed. Pizarro et al.
27 have shown that low brain natriuretic
peptide levels (,105 pg/mL) are associated with a stable disease
course whereas higher levels may predict an unfavourable
outcome. A good exercise tolerance has been shown to be
associated with a higher event-rate.
28 Left atrial size may also be
related to outcome. Recently, Tribouilloy et al.
29 have shown
that a LV end-systolic diameter ≥40 mm is independently associ-
ated with increased mortality under medical management and
after surgery. Current European guidelines recommend mitral
valve surgery when the LV end-systolic diameter is larger than
45 mm as compared with 40 mm for North American Guidelines
and these data favour the latter approach.
22–23 Recent data from
the Mayo group also suggest superior recovery of long-term LV
ejection fraction following early mitral valve repair when the pre-
operative ejection fraction is ≥65% (current guidelines rec-
ommend surgery when the ejection fraction is ≤60%).
30
Referral of patients with
symptoms and/or left ventricular
dysfunction
Symptoms and LV dysfunction are guideline triggers for surgical
referral of patients with severe mitral valve regurgitation.
22–23
Interestingly, recent studies have documented a widespread discor-
dance in ‘real world’ surgical referral of patients who have an
obvious Class I indication for surgery. In 2007, Mirabel et al.
found that 49% of patients with symptomatic mitral regurgitation
of various etiologies from the Euro Heart Survey were denied sur-
gical referral. Although frequently unjustiﬁed, advanced age,
co-morbidities, and an abnormal ejection fraction were the argu-
ments used to deny surgery.
31 Detaint and colleagues later ident-
iﬁed 101 patients within the Euro Heart Survey with isolated
severe non-ischaemic mitral regurgitation and found intervention
was ‘underused’ in 29 patients (29%) although they had no ident-
iﬁed co-morbidities and fulﬁlled guideline recommendation criteria
for surgery.
23 Toledano et al.
32 surveyed approximately 300 cardi-
ologists in Canada, half of whom were in a university practice
whereas the other half were in a community setting to gauge
their knowledge of North American referral guidelines of patients
with severe mitral valve regurgitation. Nearly 40% of those cardi-
ologists indicated that they would wait for the ejection fraction
to fall below 40% or wait for symptoms to occur before referring
an asymptomatic patient for surgery with severe mitral valve regur-
gitation, despite a Class I guideline recommendation for referral if
the ejection fraction is equal to or falls below 60%. Recently, Bach
et al.
33 assessed the frequency at which adult patients at the Uni-
versity of Michigan with severe mitral valve regurgitation documen-
ted on an echocardiogram were denied surgery. Fifty-three of 112
patients with severe degenerative mitral regurgitation were not
referred for surgery, although 39 of 53 patients (74%) had one
or more indications for surgical intervention according to
current North American guidelines.
22 Interestingly, no patients
that were referred to a surgeon for evaluation were thought to
have a risk too high for surgical intervention during the study
period, yet several patients ‘denied surgical referral’ subsequently
died. The authors concluded that much of the ‘perceived risks’
leading to a denial of referral were incorrectly interpreted by car-
diologists or other referring physicians. All of these data point
towards the need for continued medical education of practicing
Degenerative mitral valve regurgitation 1961clinicians to increase familiarity with current guidelines, which will
lead to more appropriate referral of patients to surgery.
Who should operate
It is well accepted that the majority of patients with degenerative
mitral valve disease who require surgery will have an improved
quality of life with less morbidity as well as better long-term survi-
val if a valve repair as opposed to replacement is performed.
34–37
This is related primarily to prosthesis-related morbidity, including
higher re-operation rates, and the need for aggressive anticoagula-
tion. It is sobering to note that even in developed countries, mitral
valve replacement remains frequent in the setting of degenerative
disease. Gammie et al.
38 reported that the repair rate for patients
(n ¼ 47 126) with isolated mitral regurgitation in the Society of
Thoracic Surgeons (STS) Adult Cardiac Surgery Database rose
from 51 to 69% between January 2000 and December 2007.
Similar repair rates in the 50% range were documented in the
Euro Heart Survey. The reality is that mitral valve replacement
continues to be performed far too frequently in the modern era
of reconstructive valve surgery.
39
Many recent reports document repair rates in excess of 90% in
centres highly skilled in mitral valve repair,
40–42 suggesting an
ongoing ‘gap’ in best practice surgical care of patients with degenera-
tive disease of at least 20%, which translates into a signiﬁcant inci-
dence of unnecessary mitral valve replacement. This quality
measure reinforces a recommendation in the current North Amer-
ican guidelines: ‘...cardiologists are strongly encouraged to refer
patients who are candidates for mitral valve repair, to surgical
centers experienced in performing mitral valve repair’.
22 Others
have suggested that patients with Barlow’s valve disease (which typi-
cally present with more complex lesions) be speciﬁcally targeted for
referral to mitral valve ‘reference surgeons’.
43–45 Since patients with
Barlow’s disease are typically younger and therefore likely to have
the greatest beneﬁt from valve repair instead of replacement, this
strategy seems to be particularly relevant. The localization of
leaﬂet prolapse (posterior, anterior, or bileaﬂet) is also of prognos-
tic relevance since many reported series suggest much lower repair
rates for anterior or bileaﬂet prolapse compared with posterior
leaﬂet prolapse.
45–47 Taking these factors into consideration
allows a recommendation for targeted surgeon referral of certain
patients with degenerative disease (Table 1).
Recent studies have documented that operative mortality
rates and perioperative morbidity are lower in high volume
mitral surgical centres, providing additional emphasis on a best
standard practice of trying to concentrate surgical volume of
degenerative mitral valve disease in selected centres.
48 Although
high volume is also generally associated with higher rates of
mitral valve repair, this is not always the case. In a report published
early this year from the Society for Cardiothoracic Surgery in
Great Britain and Ireland involving over 5000 mitral operations
for degenerative disease performed in either country over a
6-year-period, one of the 10 highest volume centres had a mitral
valve repair rate of ,40%.
49 Furthermore, even in high volume
mitral repair centres, it is important to differentiate surgical exper-
tise among individual surgeons. In a single-institution series of more
than 3200 mitral surgeries, although the institutional repair rate
was  93%, in a multivariate analysis of the individual surgeon’s
performances, only one surgeon in this institution was predictive
of a higher rate of repair.
36
Ongoing assessment of actual vs. predicted repair rates as
well as quality of repair judged by residual mitral regurgitation
rates are also important quality measures. Today no more than
5–10% of patients should undergo an ‘un-anticipated replacement’
or have more than mild residual regurgitation if operated on in a
‘reference centre’.
40 Particularly in the asymptomatic patient, the
role of such assessments of quality by means other than mortality
rates (which are around 1% in contemporary practice) will take on
increasing importance.
Current operative strategies
and results
Mitral valve repair operative strategies and techniques continue to
evolve, with signiﬁcant changes seen over the past decade.
Surgical access
Traditionally, mitral valve repair procedures have been performed
through a 15–20 cm skin incision and full median sternotomy.
Other less invasive approaches, including limited sternotomy or
small skin incision (8–10 cm)-full sternotomy, and right sided mini-
thoracotomies with or without video assistance (Figure 3) are now
successfully performed in many expert centres.
41–42,50–52 These
approaches are associated with higher patient cosmetic satisfac-
tion; lesser blood transfusion has been reported in some series,
at the expense of longer cross-clamp times.
The right thoracotomy approach is often used in the redo
setting, as it avoids the need for repeat sternotomy and requires
less dissection of the heart. Completely endoscopic robotic valve
repair has been reported to be feasible and reproducible in
expert centres
53 and has been embraced in selected high volume
Table 1 Targeted surgeon referral: degenerative
mitral valve disease
D.H. Adams et al. 1962centres, particularly in the USA. Higher costs, undocumented
beneﬁt, and the extensive learning curve associated with robotic
approaches likely explain slow adoption.
54
Repair techniques
The goal of a mitral valve repair procedure for degenerative
disease follows two fundamental principles: restore a good
surface of leaﬂet coaptation and correct for annular dilata-
tion.
55–56 A leaﬂet coaptation line of 5–8 mm is considered essen-
tial to provide a durable repair result. To select the most
appropriate repair technique a complete understanding of the
underlying degenerative aetiology, anatomical lesions, and leaﬂet
dysfunction (excess or restricted leaﬂet motion) is mandatory.
Intraoperative transoesophageal 2D and increasingly real time 3D
transoesophageal echocardiography is applied to guide the pro-
cedure and conﬁrm a good result.
14–15
In terms of valve repair procedures, two paradigms have
emerged with strong proponents. Carpentier’s techniques which
generally involve resection of abnormal or pathologic tissue with
precise reconstruction toward essentially ‘normal valve anatomy’
(Figure 4) remain the most commonly performed world-wide,
and are associated with excellent long-term outcomes.
10,55–58 In
the most common scenario, isolated prolapse of the posterior
leaﬂet is treated by a limited triangular or quadrangular leaﬂet
resection, including the respective elongated or ruptured
chordae. The remnant leaﬂet margins are then readapted using
interrupted sutures. If larger resections of abnormal tissue are
required such as seen in Barlow’s disease, then the annulus is com-
pressed with additional interrupted sutures to narrow its circum-
ference resulting in less tension on residual reconstructed leaﬂet
segments.
10 All resections of tissue are targeted to restore the
normal height and shape of residual leaﬂet segments, and to
restore the normal relationship of anterior and posterior leaﬂet
surface area to the normal annular dimension for a given
patient. This is critical to avoid systolic anterior motion of the
anterior leaﬂet after valve repair.
59–60 If residual prolapse
remains despite tailored resections of abnormal tissue, then trans-
fer of secondary chords to the free margin of the same segment,
or chordal transposition from one segment to another is per-
formed. For example, in the later scenario a ‘ﬂip’ of a small
segment of normal posterior leaﬂet with chords to an opposing
segment of a prolapsing anterior leaﬂet segment can restore
normal leaﬂet motion.
61
An emerging paradigm of ‘respect rather than resect’ tissue has
become popular in recent years, and is based on the use of poly-
tetraﬂuoroethylene (PTFE) neochordae to reconstruct support of
the free edge of prolapsing segments, and ‘displacing’ abnormal
excess tissue into the ventricle to ensure a good surface of coapta-
tion without systolic motion of the anterior leaﬂet.
62–63 Variations
of this technique have been described, and a ‘loop technique’
where the PTFE is anchored into a papillary muscle tip and then
branches or ‘loops’ are attached to the free edge mimicking a
chordal fan is perhaps the most widely used (Figure 4). Depending
on the individual anatomy the neochordae are anchored on the
anterior or posterior or papillary muscle heads in their ﬁbrous
portion, respecting a policy of not crossing the midline or individ-
ual native chordae in order to prevent excess traction on the
leaﬂet margin. In the case of signiﬁcant excess posterior leaﬂet
height, the neochordae are made short enough to displace the
prolapsing segment into the left ventricle, to ensure a large
surface of coaptation for the anterior leaﬂet while preventing
anterior leaﬂet displacement in the outﬂow tract. Early results
with have been encouraging and no or limited leaﬂet resection in
combination with PTFE loops is now a preferred technique in
many centres today. The simplicity of the technique is particularly
relevant in small access incisions where more advanced Carpentier
techniques may prove challenging (Figure 5).
Calciﬁcation of the chordae, papillary muscles, leaﬂets, and
annulus may occur in the setting of degenerative valve disease.
17
In general, debridement of calciﬁed tissue is required to restore
a good mobility to leaﬂet tissue, and to ensure an adequate
surface of coaptation. Mitral annular calciﬁcation can pose a
special challenge to valve reconstruction, particularly when it is
diffuse. In certain circumstances it is possible to ‘respect’ the
calcium, placing pledgeted sutures on the ventricular side of the
calcium and passing them through the ring on the atrial side. Some-
times it is necessary to perform an ‘en bloc’ resection of the
calcium bar in the annulus, separating the atrioventricular groove.
17
Regardless of the leaﬂet and chordal techniques employed, a
prosthetic ring or band annuloplasty that restores the normal cir-
cumference and shape of the mitral valve to match the available
leaﬂet tissue is a mainstay of all repair procedures.
57,64–65 The
ﬁbrous skeleton of the heart is not contiguous around the pos-
terior aspect of the mitral annulus, so long-standing regurgitation
associated with ventricular and atrial enlargement leads to patho-
logic dilatation of the mitral annulus, particularly along the pos-
terior aspect of the valve. Regardless of the type of annular
prosthesis (complete ring, partial posterior band; rigid, semi-rigid,
or ﬂexible), most surgeons measure the surface of the anterior
Figure 3 Mitral surgery via right thoracotomy. The patient is in
a supine position, and cannulated for cardiopulmonary bypass via
the groin vessels. The valve is exposed through a right mini-
thoracotomy and visualization is assisted by a videoscope.
Shown in the inset is the aorta clamped, with a caridioplegia
needle inserted in the aorta, and the mitral valve as seen by
the surgeon with the atrium opened.
Degenerative mitral valve regurgitation 1963leaﬂet with a sizer to estimate the appropriate ring size for the
amount of leaﬂet tissue, although a ‘standard length’ band has
been employed by some groups with excellent results.
66 Failure
to perform an annuloplasty at the time of mitral valve repair is
one of the strongest predictors of failure resulting in recurrent
moderate or severe mitral valve regurgitation.
67 This may have
important implications for percutaneous techniques that primarily
attempt to address prolapse by attaching opposing leaﬂets without
concomitantly changing the shape of the annulus.
Mitral valve replacement
In contemporary practice at the reference level, mitral valve repla-
cement for degenerative disease in a primary operation should be a
rare. Many current reports document repair rates in excess of
90%, regardless of lesions or associated leaﬂet dysfunction.
40–42
The most common scenario for a replacement in a high-volume
reference centre should be an end-stage Barlow deformity, typi-
cally seen in older patients with long-standing disease. This scen-
ario is actually uncommon, and if identiﬁed preoperatively should
lead to a careful discussion regarding the possibility of replacement,
and assurance that the patient has a Class I indication for surgery. If
valve replacement is necessary, annular-papillary continuity should
be preserved by performing a chordal sparring procedure.
68
Although calciﬁed leaﬂet segments require resection, non-calciﬁed
segments with intact chords are incorporated into the annulus
with sutures that are used to implant the prosthesis.
Mitral valve regurgitation
following mitral valve repair
All patients undergoing mitral valve repair should have a post-
repair intraoperative transoesophageal echocardiogram to
determine the immediate success of the procedure.
69 A ﬁnding
of more than mild mitral regurgitation should lead the
surgeon, except in certain high-risk patients, to consider valve
re-exploration to identify the source of residual regurgitation.
The most common reasons for a residual post-repair leak are
uncorrected prolapse, separation of a leaﬂet cleft or indentation,
a defect in a leaﬂet to leaﬂet closure line, or a perforation of a
leaﬂet from a ring suture near the leaﬂet hinge. In each of these
circumstances, an additional repair technique can address the
cause of valve regurgitation leading to a successful result. The
other scenario that should be ruled out in residual mitral
Figure 4 Triangular resection and ring annuloplasty. (A) Fibroelastic deﬁciency with P2 (posterior middle scallop) prolapse. (B) Dashed lines
represent area of leaﬂet to be excised. (C) Reconstructed leaﬂet after triangular resection. (D) Completed repair after ring annuloplasty.
Figure 5 Gore-Tex loop technique and ring annuloplasty. (A) Fibroelastic deﬁciency with A3 (anterior lateral scallop prolapse). (B) Gore-Tex
loops are constructed, and the apparatus is attached to the ﬁbrous tip of the papillary muscle. (C) Individual loops are attached to the prolapsing
segment margin. (D) Completed repair after ring annuloplasty.
D.H. Adams et al. 1964regurgitation following mitral valve regurgitation is displacement of
the anterior leaﬂet towards the outﬂow tract. Systolic anterior
motion is caused by an excess of leaﬂet tissue in relation to the
oriﬁce area of the mitral valve, and is caused by inappropriate
ring sizing, or an excess of residual leaﬂet height, usually involving
the posterior leaﬂet.
59,60 Occasionally systolic anterior motion
resolves with volume loading and increasing afterload, but if it is
persistent, evidenced by residual mitral regurgitation and a signiﬁ-
cant outﬂow tract gradient, the valve should be reoperated on.
The main surgical strategies to address systolic anterior motion
are leaﬂet shortening, or posterior leaﬂet ‘displacement’ of
excess leaﬂet height into the ventricle and out of the oriﬁce
using a short PTFE chordae. A larger mitral ring annuloplasty
device should also be inserted if there is a question about inap-
propriate sizing during the initial repair procedure.
All patients undergoing mitral valve repair should also have a
pre-discharge transthoracic echocardiogram to assess the repair
result under normal loading and pressure conditions.
69 Moderate
or greater regurgitation should lead the surgeon in most circum-
stances to consider valve re-exploration after careful risk assess-
ment of the individual patient. It is always better to address
residual signiﬁcant mitral regurgitation at this point, instead of
months or years down the road when the re-operation is more
complicated due to adhesions.
An annual echocardiogram is usually performed in patients
who have undergone successful mitral valve repair. A new
mitral regurgitation not seen on early transthoracic follow-up
should be categorized as recurrent mitral regurgitation. The
most common cause of recurrent mitral regurgitation is pro-
gression of the degenerative process which led to the original
valve dysfunction. Leaﬂet shortening or scarring is another poten-
tial source of recurrent regurgitation, as is a ring dehiscence.
Mitral valve endocarditis, although rare, is also in the differential
of recurrent regurgitation following a successful mitral valve
repair. Pannus in-growth triggered by the mitral annuloplasty
ring is another rare but described cause of failure following a
mitral valve repair.
70 Haemolysis in the setting of post-operative
mitral regurgitation is another possible outcome that could lead
to the need for mitral valve re-operation.
Although mitral valve re-repair in the setting of chronic recur-
rent mitral regurgitation has been reported, it is highly dependent
on the surgical expertise of the group performing the procedure.
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In many circumstances a re-repair of the mitral valve is feasible
depending on the anatomy and well identiﬁed mechanisms of the
recurrent mitral regurgitation.
Surgical results
Although freedom from re-operation is very low in degenerative
mitral valve surgery (15 year freedom from re-operation is
around 95%),
55 recent studies have documented the potential
for recurrence of signiﬁcant mitral valve regurgitation. Studies by
Flameng et al. and David et al. suggest that a return of moderate
to severe mitral regurgitation occurs in 1–2% of patients per
year during mid-term follow-up.
55,67,72–74 This observation
places renewed emphasis on expert mitral surgical repair initially
(not only mitigating mitral regurgitation procedurally, but ensuring
a long surface of leaﬂet coaptation to minimize the risks of a late
failure), and also on the need to continue to evolve surgical
strategies that will optimize long-term mitral valve repair results.
Long-term survival following mitral valve repair is similar to age
matched controls provided the operation is done in a timely
fashion before the onset of symptoms, ventricular dysfunction or
atrial ﬁbrillation.
34–35,75–76 Patients undergoing mitral valve
surgery with advanced symptoms do poorly compared with less
symptomatic patients, so surgery should always be recommended
at the onset of symptoms in otherwise low-risk patients. An ejec-
tion fraction of ≤60% is a trigger for referral to surgery, as long-
term survival is compromised in patients after mitral surgery if
the initial ejection fraction is compromised beyond this point.
Atrial ﬁbrillation is a more controversial indication for surgical
referral, but if present at the time of surgery, patients should prob-
ably also undergo a concomitant modiﬁed Maze procedure utilizing
cryothermy or radiofrequency, although evidence-based data are
lacking.
77–78 Persistent atrial ﬁbrillation after mitral valve repair is
associated with long-term morbidity including stroke as well as
mortality, and these patients require careful anticoagulation
monitoring.
79–80
Best practice revolution
Prevailing data suggest many patients with degenerative mitral valve
disease do not receive state-of-the-art care. Accumulating evi-
dence documents a reluctance of many cardiologists and physicians
following patients with mitral valve regurgitation to refer them for
surgery in a timely fashion, when the maximal beneﬁt from a suc-
cessful mitral valve repair would be realized. The reasons behind
this are certainly multi-factorial, and probably include unawareness
of basic concepts in and recent changes to guidelines and a lack of
conﬁdence in or poor understanding of modern surgical therapy
and results. Both suggest the need for broad continued education
with regard to the indications for intervention for mitral valve
regurgitation. The implementation of dedicated valve clinics
should be encouraged when feasible; a signiﬁcant outcome
beneﬁt can be achieved when experience is widened with
larger patient volumes. A close cooperation between internists,
imagers, cardiologists, and cardiac surgeons should be promoted,
centred on guideline-driven practice.
Despite surgical progress seen in increasing repair rates, lower
mortality rates, and less invasive approaches, far too many
patients continue to be subjected to unnecessary valve replace-
ment procedures. In this modern era of imaging and degenerative
disease differentiation, it should be very uncommon for a patient
with mitral valve prolapse to have an unexpected valve replace-
ment based on operative ﬁndings; if the surgeon or imager
thinks the chances are ,90% for a successful repair, they
should refer the patient (particularly any asymptomatic patient
or a young patient with Barlow’s valve disease) to a reference
surgeon in a regional reference mitral valve centre; hopefully
future evidence of better patient outcomes will support these
recommendations and lead to their incorporation into daily prac-
tice. There are numerous ‘medical geo-political and ﬁnancial bar-
riers’ to such a transparency in surgical referral, but the patient
with degenerative mitral valve disease deserves the best possible
Degenerative mitral valve regurgitation 1965chance for a repair procedure, which is associated with lower
long-term morbidity and mortality compared with valve replace-
ment in a majority of patients.
Funding
Funding to pay the Open access publication charges for this article was
provided by the Department of Cardiothoracic Surgery, Mount Sinai
School of Medicine.
Conﬂict of interest: D.H.A. is the inventor of mitral annuloplasty
rings; has received royalty agreements from Edwards Lifesciences
LLC; is co-principal investigator for Medtronic Core-Valve US Pivotal
Trial.
References
1. Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet 2009;373:
1382–1394.
2. Anders S, Said S, Schulz F, Puschel K. Mitral valve prolapse syndrome as cause of
sudden death in young adults. Forensic Sci Int 2007;171:127–130.
3. Carabello BA. The current therapy for mitral regurgitation. J Am Coll Cardiol 2008;
52:319–326.
4. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M,
Nkomo V, Scott C, Schaff HV, Tajik AJ. Quantitative determinants of the
outcome of asymptomatic mitral regurgitation. N Engl J Med 2005;352:875–883.
5. Kang DH, Kim JH, Rim JH, Kim MJ, Yun SC, Song JM, Song H, Choi KJ, Song JK,
Lee JW. Comparison of early surgery versus conventional treatment in asympto-
matic severe mitral regurgitation. Circulation 2009;119:797–804.
6. Montant P, Chenot F, Robert A, Vancraeynest D, Pasquet A, Gerber B,
Noirhomme P, El Khoury G, Vanoverschelde JL. Long-term survival in asympto-
matic patients with severe degenerative mitral regurgitation: a propensity score-
based comparison between an early surgical strategy and a conservative treat-
ment approach. J Thorac Cardiovasc Surg 2009;138:1339–1348.
7. Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M,
Maurer G, Baumgartner H. Outcome of watchful waiting in asymptomatic
severe mitral regurgitation. Circulation 2006;113:2238–2244.
8. Adams DH, Anyanwu AC. Seeking a higher standard for degenerative mitral valve
repair: begin with etiology. J Thorac Cardiovasc Surg 2008;136:551–556.
9. Anyanwu AC, Adams DH. Etiologic classiﬁcation of degenerative mitral valve
disease: Barlow’s disease and ﬁbroelastic deﬁciency. Semin Thorac Cardiovasc
Surg 2007;19:90–96.
10. Carpentier A, Chauvaud S, Fabiani JN, Deloche A, Relland J, Lessana A,
D’Allaines C, Blondeau P, Piwnica A, Dubost C. Reconstructive surgery of mitral
valve incompetence: ten-year appraisal. J Thorac Cardiovasc Surg 1980;79:338–348.
11. Fornes P, Heudes D, Fuzellier JF, Tixier D, Bruneval P, Carpentier A. Correlation
between clinical and histologic patterns of degenerative mitral valve insufﬁciency:
a histomorphometric study of 130 excised segments. Cardiovasc Pathol 1999;8:
81–92.
12. Barlow JB, Pocock WA. The signiﬁcance of late systolic murmurs and mid-late sys-
tolic clicks. Md State Med J 1963;12:76–77.
13. Carpentier A, Lacour-Gayet F, Camilleri J. Fibroelastic dysplasia of the mitral
valve: an anatomical and clinical entity. Circulation 1982;3:307.
14. Adams DH, Anyanwu AC, Sugeng L, Lang RM. Degenerative mitral valve regurgi-
tation: surgical echocardiography. Curr Cardiol Rep 2008;10:226–232.
15. O’Gara P, Sugeng L, Lang R, Sarano M, Hung J, Raman S, Fischer G, Carabello B,
Adams D, Vannan M. The role of imaging in chronic degenerative mitral regurgita-
tion. JACC Cardiovasc Imaging 2008;1:221–237.
16. Barlow JB, Pocock WA. Billowing, ﬂoppy, prolapsed or ﬂail mitral valves? Am J
Cardiol 1985;55:501–502.
17. Carpentier AF, Pellerin M, Fuzellier JF, Relland JY. Extensive calciﬁcation of the
mitral valve anulus: pathology and surgical management. J Thorac Cardiovasc Surg
1996;111:718–729. discussion 729–730.
18. Hutchins GM, Moore GW, Skoog DK. The association of ﬂoppy mitral valve with
disjunction of the mitral annulus ﬁbrosus. N Engl J Med 1986;314:535–540.
19. Monin JL, Dehant P, Roiron C, Monchi M, Tabet JY, Clerc P, Fernandez G,
Houel R, Garot J, Chauvel C, Gueret P. Functional assessment of mitral regurgita-
tion by transthoracic echocardiography using standardized imaging planes diag-
nostic accuracy and outcome implications. J Am Coll Cardiol 2005;46:302–309.
20. Pepi M, Tamborini G, Maltagliati A, Galli CA, Sisillo E, Salvi L, Naliato M,
Porqueddu M, Parolari A, Zanobini M, Alamanni F. Head-to-head comparison
of two- and three-dimensional transthoracic and transesophageal
echocardiography in the localization of mitral valve prolapse. J Am Coll Cardiol
2006;48:2524–2530.
21. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA,
Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ,
Waggoner A, Weissman NJ. Recommendations for evaluation of the severity of
native valvular regurgitation with two-dimensional and Doppler echocardiogra-
phy. J Am Soc Echocardiogr 2003;16:777–802.
22. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD,
Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM,
Shah PM, Shanewise JS. 2008 focused update incorporated into the ACC/AHA
2006 guidelines for the management of patients with valvular heart disease: a
report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for
the management of patients with valvular heart disease). Endorsed by the Society
of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and
Interventions, and Society of Thoracic Surgeons. JA mC o l lC a r d i o l2008;52:e1–e142.
23. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G,
Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L,
Wenink A. Guidelines on the management of valvular heart disease: the task
force on the management of valvular heart disease of the European society of car-
diology. Eur Heart J 2007;28:230–268.
24. Adams DH, Anyanwu AC. Valve Disease: Asymptomatic mitral regurgitation:
does surgery save lives? Nat Rev Cardiol 2009;6:330–332.
25. Detaint D, Iung B, Lepage L, Messika-Zeitoun D, Baron G, Tornos P,
Gohlke-Barwolf C, Vahanian A. Management of asymptomatic patients with
severe non-ischaemic mitral regurgitation. Are practices consistent with guide-
lines? Eur J Cardiothorac Surg 2008;34:937–942.
26. Schaff HV. Asymptomatic severe mitral valve regurgitation: observation or oper-
ation? Circulation 2009;119:768–769.
27. Pizarro R, Bazzino OO, Oberti PF, Falconi M, Achilli F, Arias A, Krauss JG,
Cagide AM. Prospective validation of the prognostic usefulness of brain natriure-
tic peptide in asymptomatic patients with chronic severe mitral regurgitation. JA m
Coll Cardiol 2009;54:1099–1106.
28. Supino PG, Borer JS, Schuleri K, Gupta A, Hochreiter C, Kligﬁeld P, Herrold EM,
Preibisz JJ. Prognostic value of exercise tolerance testing in asymptomatic chronic
nonischemic mitral regurgitation. Am J Cardiol 2007;100:1274–1281.
29. Tribouilloy C, Grigioni F, Avierinos JF, Barbieri A, Rusinaru D, Szymanski C,
Ferlito M, Tafanelli L, Bursi F, Trojette F, Branzi A, Habib G, Modena MG,
Enriquez-Sarano M. Survival implication of left ventricular end-systolic diameter
in mitral regurgitation due to ﬂail leaﬂets a long-term follow-up multicenter
study. J Am Coll Cardiol 2009;54:1961–1968.
30. Suri RM, Schaff HV, Dearani JA, Sundt TM, Daly RC, Mullany CJ,
Enriquez-Sarano M, Orszulak TA. Recovery of left ventricular function after sur-
gical correction of mitral regurgitation caused by leaﬂet prolapse. J Thorac Cardi-
ovasc Surg 2009;137:1071–1076.
31. Mirabel M, Iung B, Baron G, Messika-Zeitoun D, Detaint D, Vanoverschelde JL,
Butchart EG, Ravaud P, Vahanian A. What are the characteristics of patients
with severe, symptomatic, mitral regurgitation who are denied surgery? Eur
Heart J 2007;28:1358–1365.
32. Toledano K, Rudski LG, Huynh T, Beique F, Sampalis J, Morin JF. Mitral regurgita-
tion: determinants of referral for cardiac surgery by Canadian cardiologists. Can J
Cardiol 2007;23:209–214.
33. Bach DS, Awais M, Gurm HS, Kohnstamm S. Failure of guideline adherence for
intervention in patients with severe mitral regurgitation. J Am Coll Cardiol 2009;
54:860–865.
34. David TE, Ivanov J, Armstrong S, Rakowski H. Late outcomes of mitral valve repair
for ﬂoppy valves: Implications for asymptomatic patients. J Thorac Cardiovasc Surg
2003;125:1143–1152.
35. Enriquez-Sarano M, Schaff HV, Orszulak TA, Tajik AJ, Bailey KR, Frye RL. Valve
repair improves the outcome of surgery for mitral regurgitation. A multivariate
analysis. Circulation 1995;91:1022–1028.
36. Gillinov AM, Blackstone EH, Nowicki ER, Slisatkorn W, Al-Dossari G,
Johnston DR, George KM, Houghtaling PL, Grifﬁn B, Sabik JF 3rd, Svensson LG.
Valve repair versus valve replacement for degenerative mitral valve disease.
J Thorac Cardiovasc Surg 2008;135:885–893. 893 e881–882.
37. Suri RM, Schaff HV, Dearani JA, Sundt TM 3rd, Daly RC, Mullany CJ,
Enriquez-Sarano M, Orszulak TA. Survival advantage and improved durability of
mitral repair for leaﬂet prolapse subsets in the current era. Ann Thorac Surg
2006;82:819–826.
38. Gammie JS, Sheng S, Grifﬁth BP, Peterson ED, Rankin JS, O’Brien SM, Brown JM.
Trends in mitral valve surgery in the United States: results from the Society of
Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg 2009;87:
1431–1437. discussion 1437–1439.
39. IungB,BaronG,ButchartEG,DelahayeF,Gohlke-BarwolfC,LevangOW,TornosP,
Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective
D.H. Adams et al. 1966survey of patients with valvular heart disease in Europe: The Euro Heart Survey on
Valvular Heart Disease. Eur Heart J 2003;24:1231–1243.
40. Adams DH, Anyanwu AC, Rahmanian PB, Abascal V, Salzberg SP, Filsouﬁ F. Large
annuloplasty rings facilitate mitral valve repair in Barlow’s disease. Ann Thorac Surg
2006;82:2096–2100. discussion 2101.
41. Gammie JS, Bartlett ST, Grifﬁth BP. Small-incision mitral valve repair: safe, durable,
and approaching perfection. Ann Surg 2009;250:409–415.
42. Seeburger J, Borger MA, Falk V, Kuntze T, Czesla M, Walther T, Doll N,
Mohr FW. Minimal invasive mitral valve repair for mitral regurgitation: results
of 1339 consecutive patients. Eur J Cardiothorac Surg 2008;34:760–765.
43. Adams DH, Anyanwu AC. The cardiologist’s role in increasing the rate of mitral
valve repair in degenerative disease. Curr Opin Cardiol 2008;23:105–110.
44. Bridgewater B, Hooper T, Munsch C, Hunter S, von Oppell U, Livesey S, Keogh B,
Wells F, Patrick M, Kneeshaw J, Chambers J, Masani N, Ray S. Mitral repair best
practice: proposed standards. Heart 2006;92:939–944.
45. McCarthy PM. When is your surgeon good enough? When do you need a
‘referent surgeon’? Curr Cardiol Rep 2009;11:107–113.
46. Manda J, Kesanolla SK, Hsuing MC, Nanda NC, Abo-Salem E, Dutta R, Laney CA,
Wei J, Chang CY, Tsai SK, Hansalia S, Yin WH, Young MS. Comparison of real
time two-dimensional with live/real time three-dimensional transesophageal
echocardiography in the evaluation of mitral valve prolapse and chordae
rupture. Echocardiography 2008;25:1131–1137.
47. Umakanthan R, Leacche M, Petracek MR, Kumar S, Solenkova NV, Kaiser CA,
Greelish JP, Balaguer JM, Ahmad RM, Ball SK, Hoff SJ, Absi TS, Kim BS,
Byrne JG. Safety of minimally invasive mitral valve surgery without aortic cross-
clamp. Ann Thorac Surg 2008;85:1544–1549. discussion 1549–1550.
48. Gammie JS, O’Brien SM, Grifﬁth BP, Ferguson TB, Peterson ED. Inﬂuence of hos-
pital procedural volume on care process and mortality for patients undergoing
elective surgery for mitral regurgitation. Circulation 2007;115:881–887.
49. Bridgewater B, Keogh B, Kinsman R, Walton P. Sixth national adult cardiac surgical
database report of great Britain and Ireland. 2009.
50. Casselman FP, Van Slycke S, Dom H, Lambrechts DL, Vermeulen Y, Vanermen H.
Endoscopic mitral valve repair: feasible, reproducible, and durable. J Thorac Cardi-
ovasc Surg 2003;125:273–282.
51. Modi P, Rodriguez E, Hargrove WC 3rd, Hassan A, Szeto WY, Chitwood WR Jr.
Minimally invasive video-assisted mitral valve surgery: a 12-year, 2-center experi-
ence in 1178 patients. J Thorac Cardiovasc Surg 2009;137:1481–1487.
52. Mohr FW, Falk V, Diegeler A, Walther T, van Son JA, Autschbach R. Minimally
invasive port-access mitral valve surgery. J Thorac Cardiovasc Surg 1998;115:
567–574. discussion 574–566.
53. Chitwood WR Jr, Rodriguez E, Chu MW, Hassan A, Ferguson TB, Vos PW,
Nifong LW. Robotic mitral valve repairs in 300 patients: a single-center experi-
ence. J Thorac Cardiovasc Surg 2008;136:436–441.
54. Cheng W, Fontana GP, De Robertis MA, Mirocha J, Czer LS, Kass RM, Trento A.
Is robotic mitral valve repair a reproducible approach? J Thorac Cardiovasc Surg
2010;139:628–633.
55. Braunberger E, Deloche A, Berrebi A, Abdallah F, Celestin JA, Meimoun P,
Chatellier G, Chauvaud S, Fabiani JN, Carpentier A. Very long-term results
(more than 20 years) of valve repair with carpentier’s techniques in nonrheumatic
mitral valve insufﬁciency. Circulation 2001;104:I8–I11.
56. Carpentier A. Cardiac valve surgery—the ‘French correction’. J Thorac Cardiovasc
Surg 1983;86:323–337.
57. Carpentier A, Deloche A, Dauptain J, Soyer R, Blondeau P, Piwnica A, Dubost C,
McGoon DC. A new reconstructive operation for correction of mitral and tricus-
pid insufﬁciency. J Thorac Cardiovasc Surg 1971;61:1–13.
58. Filsouﬁ F, Carpentier A. Principles of reconstructive surgery in degenerative mitral
valve disease. Semin Thorac Cardiovasc Surg 2007;19:103–110.
59. Jebara VA, Mihaileanu S, Acar C, Brizard C, Grare P, Latremouille C, Chauvaud S,
Fabiani JN, Deloche A, Carpentier A. Left ventricular outﬂow tract obstruction
after mitral valve repair. Results of the sliding leaﬂet technique. Circulation 1993;
88:II30–II34.
60. Mihaileanu S, Marino JP, Chauvaud S, Perier P, Forman J, Vissoat J, Julien J,
Dreyfus G, Abastado P, Carpentier A. Left ventricular outﬂow obstruction
after mitral valve repair (Carpentier’s technique). Proposed mechanisms of
disease. Circulation 1988;78:I78–I84.
61. Gillinov AM, Cosgrove DM. Chordal transfer for repair of anterior leaﬂet pro-
lapse. Semin Thorac Cardiovasc Surg 2004;16:169–173.
62. Falk V, Seeburger J, Czesla M, Borger MA, Willige J, Kuntze T, Doll N, Borger F,
Perrier P, Mohr FW. How does the use of polytetraﬂuoroethylene neochordae
for posterior mitral valve prolapse (loop technique) compare with leaﬂet resec-
tion? A prospective randomized trial. J Thorac Cardiovasc Surg 2008;136:1205;
discussion 1205–1206.
63. Seeburger J, Kuntze T, Mohr FW. Gore-tex chordoplasty in degenerative mitral
valve repair. Semin Thorac Cardiovasc Surg 2007;19:111–115.
64. Carpentier AF, Lessana A, Relland JY, Belli E, Mihaileanu S, Berrebi AJ, Palsky E,
Loulmet DF. The ‘physio-ring’: an advanced concept in mitral valve annuloplasty.
Ann Thorac Surg 1995;60:1177–1185; discussion 1185–1176.
65. Gillinov AM, Cosgrove DM 3rd, Shiota T, Qin J, Tsujino H, Stewart WJ,
Thomas JD, Porqueddu M, White JA, Blackstone EH. Cosgrove-Edwards Annulo-
plasty System: midterm results. Ann Thorac Surg 2000;69:717–721.
66. Brown ML, Schaff HV, Li Z, Suri RM, Daly RC, Orszulak TA. Results of mitral valve
annuloplasty with a standard-sized posterior band: is measuring important?
J Thorac Cardiovasc Surg 2009;138:886–891.
67. Flameng W, Herijgers P, Bogaerts K. Recurrence of mitral valve regurgitation
after mitral valve repair in degenerative valve disease. Circulation 2003;107:
1609–1613.
68. David TE, Burns RJ, Bacchus CM, Druck MN. Mitral valve replacement for mitral
regurgitation with and without preservation of chordae tendineae. J Thorac Cardi-
ovasc Surg 1984;88:718–725.
69. Anyanwu AC, Adams DH. Why do mitral valve repairs fail? J Am Soc Echocardiogr
2009;22:1265–1268.
70. Ibrahim MF, David TE. Mitral stenosis after mitral valve repair for non-rheumatic
mitral regurgitation. Ann Thorac Surg 2002;73:34–36.
71. Suri RM, Schaff HV, Dearani JA, Sundt TM 3rd, Daly RC, Mullany CJ,
Enriquez-Sarano M, Orszulak TA. Recurrent mitral regurgitation after repair:
shouldthemitralvalvebere-repaired?JThoracCardiovascSurg2006;132:1390–1397.
72. David TE. Outcomes of mitral valve repair for mitral regurgitation due to degen-
erative disease. Semin Thorac Cardiovasc Surg 2007;19:116–120.
73. David TE, Ivanov J, Armstrong S, Christie D, Rakowski H. A comparison of out-
comes of mitral valve repair for degenerative disease with posterior, anterior, and
bileaﬂet prolapse. J Thorac Cardiovasc Surg 2005;130:1242–1249.
74. Flameng W, Meuris B, Herijgers P, Herregods MC. Durability of mitral valve repair
in Barlow disease versus ﬁbroelastic deﬁciency. J Thorac Cardiovasc Surg 2008;135:
274–282.
75. Enriquez-Sarano M, Tajik AJ, Schaff HV, Orszulak TA, Bailey KR, Frye RL. Echocar-
diographic prediction of survival after surgical correction of organic mitral regur-
gitation. Circulation 1994;90:830–837.
76. Enriquez-Sarano M, Tajik AJ, Schaff HV, Orszulak TA, McGoon MD, Bailey KR,
Frye RL. Echocardiographic prediction of left ventricular function after correction
of mitral regurgitation: results and clinical implications. J Am Coll Cardiol 1994;24:
1536–1543.
77. Lee AM, Melby SJ, Damiano RJ Jr. The surgical treatment of atrial ﬁbrillation. Surg
Clin North Am 2009;89:1001–1020. x–xi.
78. Lee R, Kruse J, McCarthy PM. Surgery for atrial ﬁbrillation. Nat Rev Cardiol 2009;6:
505–513.
79. Eguchi K, Ohtaki E, Matsumura T, Tanaka K, Tohbaru T, Iguchi N, Misu K,
Asano R, Nagayama M, Sumiyoshi T, Kasegawa H, Hosoda S. Pre-operative
atrial ﬁbrillation as the key determinant of outcome of mitral valve repair for
degenerative mitral regurgitation. Eur Heart J 2005;26:1866–1872.
80. Itoh A, Kobayashi J, Bando K, Niwaya K, Tagusari O, Nakajima H, Komori S,
Kitamura S. The impact of mitral valve surgery combined with maze procedure.
Eur J Cardiothorac Surg 2006;29:1030–1035.
Degenerative mitral valve regurgitation 1966a